PMI’s FDA-approved SynCardia STAH is promising, but adoption and revenues lag; cash burn and dilution weigh. Read the full ...
North America held a dominant market position, capturing more than a 41.7% share, holding USD 3.79 billion in revenue.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback